Protocol Page


	Study ID (Protocol Number)
	CA212-002


	STUDY LOCATIONS*
	Dana Farber Cancer Institute Boston, MA 02215 Recruiting	University Of Washington School Of Medicine Seattle, WA 98195 Recruiting
	H. Lee Moffitt Cancer Center & Research Institute Tampa, FL 33612 Recruiting	Washington University School Of Medicine St. Louis, MO 63110 Terminated
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
	STUDY OVERVIEW
	The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in combination with Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in subjects with relapsed or refractory multiple myeloma.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.